Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05164471 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B
A Phase 1 study, sponsored by Spur Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05164471 is a Phase 1 study that was terminated before completion, run by Spur Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT05164471, a Phase 1 study, was terminated before completion, sponsored by Spur Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Study of FLT180a gene therapy in adults with Hemophilia B. Up to 9 patients will be enrolled to receive a single dose of FLT180a and be followed for 52 weeks. Results will confirm the dose for a future Phase 3 study.
Interventions
- GENETIC verbrinacogene setparvovec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05164471
The ClinicalTrials.gov registry entry for NCT05164471 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spur Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which verbrinacogene setparvovec is the first listed.
NCT05164471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05164471 about?
NCT05164471 is a clinical study titled "Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B". Study of FLT180a gene therapy in adults with Hemophilia B. Up to 9 patients will be enrolled to receive a single dose of FLT180a and be followed for 52 weeks. Results will confirm the dose for a future Phase 3 study.
What is the current status of trial NCT05164471?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-12-06. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT05164471?
The interventions under investigation include: verbrinacogene setparvovec (GENETIC).
Who is sponsoring clinical trial NCT05164471?
This trial is sponsored by Spur Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.